Foghorn Therapeutics (FHTX)
(Real Time Quote from BATS)
$4.88 USD
-0.12 (-2.40%)
Updated Aug 6, 2025 11:28 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Foghorn Therapeutics Inc. has a market cap of $278.71M, which represents its share price of $5.00 multiplied by its outstanding shares number of 55.74M. As a small-cap company, FHTX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
FHTX 4.88 -0.12(-2.40%)
Will FHTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FHTX
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
Other News for FHTX
FHTX: Upcoming Virtual Meeting Hosted by B. Riley
Foghorn Therapeutics management to meet virtually with B. Riley
Foghorn Therapeutics reports Q2 results
Foghorn Therapeutics Inc (FHTX) Q2 2025 Earnings: EPS of -$0.33 Meets Estimates, Revenue of $7. ...
FHTX Reports Strong Q2 Revenue and Advances Cancer Treatment Pipeline